24
Participants
Start Date
November 30, 2011
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2012
Vacc-4x low dose
80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Vacc-4x medium dose
400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Vacc-4x high dose
1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Zero dose
300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Department of Infectious Diseases, Oslo University Hospital, Oslo
Collaborators (1)
Bionor Immuno AS
INDUSTRY
Eurocine Vaccines AB
INDUSTRY
Oslo University Hospital
OTHER